Tuesday, December 26, 2017
Nanobiotix SA Announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) Application for NBTXR3, a first-in-class nanoparticle designed for direct injection into cancerous tumors, activated by stereotactic ablative radiotherapy (SABR) and administered in combination with an anti-PD1 antibody (nivolumab or pembrolizumab).
First Nanobiotix immuno-oncology trial will be conducted in the U.S.
